MB501 / Mustbio - LARVOL DELTA

MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability (SITC 2023) - "MB501 therapy yielded a complete regression (6/6) in the MC38 tumor and maintained tumor-free in rechallenge trials and well-tolerated up to a 10-fold higher dose compared to the effective dose in the same strain. Conclusions MB501 represents a promising potential as an immunotherapeutic approach, as it has demonstrated both strong efficacy and good tolerability, along with improved safety margins."

Clinical • Oncology • CD8 • GZMB • IFNG • IL2 • STAT5